Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein

B. A. Krishna; K. Spiess; E. L. Poole; B. Lau; S. Voigt; T. N. Kledal; M. M. Rosenkilde; J. H. Sinclair

doi:10.1038/ncomms14321

Nature Communications (Feb 2017)

Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein

B. A. Krishna,
K. Spiess,
E. L. Poole,
B. Lau,
S. Voigt,
T. N. Kledal,
M. M. Rosenkilde,
J. H. Sinclair

Affiliations

B. A. Krishna: Department of Medicine, Addenbrooke’s Hospital, University of Cambridge
K. Spiess: Department of Neuroscience and Pharmacology, Laboratory for Molecular Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen
E. L. Poole: Department of Medicine, Addenbrooke’s Hospital, University of Cambridge
B. Lau: Department of Medicine, Addenbrooke’s Hospital, University of Cambridge
S. Voigt: Department of Infectious Diseases, Robert Koch Institute
T. N. Kledal: Section for Virology, The National Veterinary Institute, Technical University of Denmark
M. M. Rosenkilde: Department of Neuroscience and Pharmacology, Laboratory for Molecular Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen
J. H. Sinclair: Department of Medicine, Addenbrooke’s Hospital, University of Cambridge

DOI: https://doi.org/10.1038/ncomms14321
Journal volume & issue: Vol. 8, no. 1
pp. 1 – 9

Abstract

Read online

Reactivation of human cytomegalovirus in immunosuppressed transplant patients can cause severe complications. Here, Krishnaet al. show that a fusion toxin protein that specifically binds the viral surface protein US28 can be used to kill latently infected monocytes and their progenitor cells in vitro.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal